Alta Wealth Advisors
AKBA icon

Alta Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

Alta Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$16.7K Hold
18,164
– – ﹤0.01% 181
2026
Q2 		$20.7K Buy
+18,164
New +$21.6K 0.01% 170

Other funds holding AKBA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Alta Wealth Advisors's AKBA Position: Q3 2026 in Review

Alta Wealth Advisors held its Akebia Therapeutics (AKBA) position steady in Q3 2026 at 18,164 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #181.

Alta Wealth Advisors first reported a position in AKBA in Q2 2026 and has held it in 2 quarters since. The position peaked at $20.7K in Q2 2026. 118 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Alta Wealth Advisors held 18,164 shares of Akebia Therapeutics worth $16.7K as of Q3 2026.
  • Alta Wealth Advisors left its Akebia Therapeutics share count unchanged in Q3 2026.
  • Akebia Therapeutics made up ﹤0.01% of Alta Wealth Advisors's portfolio in Q3 2026, its #181 holding.
  • Alta Wealth Advisors first reported a position in Akebia Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Alta Wealth Advisors's Akebia Therapeutics position peaked at $20.7K in Q2 2026.
  • 118 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Alta Wealth Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.